• From the Desk of the Associate Editor: Progression on Enzalutamide: Data from the PREVAIL Trial

    Enzalutamide is a second generation AR inhibitor that engages AR through the ligand binding domain, inhibiting DNA binding and AR activity. In the PREVAIL study, enzalutamide improved overall survival in chemotherapy naïve men with mCRPC, and enzalutamide is presently a standard of care for these men, with greater activity observed when used prior to docetaxel as compared to following docetaxel.  While most men respond to enzalutamide in this setting, all men develop treatment resistance between 1-3 years. This present article explores how men progress on enzalutamide, using data from the PREVAIL trial.
    Published November 17, 2017
  • GU Cancers Symposium 2014 - Poster: Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study

    SAN FRANCISCO, CA USA (UroToday.com) - Presented by Tomasz M. Beer, Andrew J. Armstrong, Cora N. Sternberg, Celestia S. Higano, Peter Iversen, Yohann Loriot, Dana E. Rathkopf, Suman Bhattacharya, Joan Carles, Johann S. De Bono, Christopher P. Evans, Anthony M. Joshua, Choung-Soo Kim, Go Kimura, Paul N. Mainwaring, Harry H. Mansbach, Kurt Miller, Sarah B. Noonberg, Peter M. Venner, and Bertrand Tombal at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

    Published February 4, 2014

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.